Referencias bibliográficas

  1. Cobb CA, Cole MP. Oxidative and nitrative stress in neurodegeneration. Neurobiol Dis. 2015 Dec;84:4–21.
  2. Gonzalez Caldito N. Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders. Front Immunol. 2023;14:1213448.
  3. Venkatesh A, Daugherty AM, Bennett IJ. Neuroimaging measures of iron and gliosis explain memory performance in aging. Hum Brain Mapp. 2021 Dec;42(17):5761–70.
  4. Aigbogun MS, Stellhorn R, Krasa H, Kostic D. Severity of memory impairment in the elderly: Association with health care resource use and functional limitations in the United States. Alzheimer’s Dement (Amsterdam, Netherlands). 2017;8:51–9.
  5. Vega Alonso T, Miralles Espí M, Mangas Reina JM, Castrillejo Pérez D, Rivas Pérez AI, Gil Costa M, et al. Prevalence of cognitive impairment in Spain: The Gómez de Caso study in health sentinel networks. Neurologia. 2018 Oct;33(8):491–8.
  6. Marvel CL, Paradiso S. Cognitive and neurological impairment in mood disorders. Psychiatr Clin [Internet]. 2004 Mar 1;27(1):19–36. Available from: https://doi.org/10.1016/S0193-953X(03)00106-0
  7. Douglas KM, Groves S, Crowe MT, Inder ML, Jordan J, Carlyle D, et al. A randomised controlled trial of psychotherapy and cognitive remediation to target cognition in mood disorders. Acta Psychiatr Scand. 2022 Mar;145(3):278–92.
  8. Kim EJ, Kim JJ. Neurocognitive effects of stress: a metaparadigm perspective. Mol Psychiatry [Internet]. 2023;28(7):2750–63. Available from: https://doi.org/10.1038/s41380-023-01986-4
  9. Craft S. Insulin resistance syndrome and Alzheimer’s disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005 Dec;26 Suppl 1:65–9.
  10. Kulshreshtha A, Alonso A, McClure LA, Hajjar I, Manly JJ, Judd S. Association of Stress With Cognitive Function Among Older Black and White US Adults. JAMA Netw Open [Internet]. 2023 Mar 7;6(3):e231860–e231860. Available from: https://doi.org/10.1001/jamanetworkopen.2023.1860
  11. Lupien SJ, Juster RP, Raymond C, Marin MF. The effects of chronic stress on the human brain: From neurotoxicity, to vulnerability, to opportunity. Front Neuroendocrinol [Internet]. 2018;49:91–105. Available from: https://www.sciencedirect.com/science/article/pii/S0091302218300098
  12. Duzel E, van Praag H, Sendtner M. Can physical exercise in old age improve memory and hippocampal function? Brain. 2016 Mar;139(Pt 3):662–73.
  13. Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine. 2021 Aug;38:100997.
  14. Shug AL, Schmidt MJ, Golden GT, Fariello RG. The distribution and role of carnitine in the mammalian brain. Life Sci. 1982 Dec;31(25):2869–74.
  15. Benton D, Donohoe RT. The influence on cognition of the interactions between lecithin, carnitine and carbohydrate. Psychopharmacology (Berl). 2004 Aug;175(1):84–91.
  16. Pennisi M, Lanza G, Cantone M, D’Amico E, Fisicaro F, Puglisi V, et al. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients. 2020 May;12(5).
  17. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol. 1986 Sep;24(9):511–6.
  18. Sershen H, Harsing LGJ, Banay-Schwartz M, Hashim A, Ramacci MT, Lajtha A. Effect of acetyl-L-carnitine on the dopaminergic system in aging brain. J Neurosci Res. 1991 Nov;30(3):555–9.
  19. Bähring R, Standhardt H, Martelli EA, Grantyn R. GABA-activated chloride currents of postnatal mouse retinal ganglion cells are blocked by acetylcholine and acetylcarnitine: how specific are ion channels in immature neurons? Eur J Neurosci. 1994 Jul;6(7):1089–99.
  20. Fariello RG, Ferraro TN, Golden GT, DeMattei M. Systemic acetyl-L-carnitine elevates nigral levels of glutathione and GABA. Life Sci. 1988;43(3):289–92.
  21. Gomez-Ramirez M, Higgins BA, Rycroft JA, Owen GN, Mahoney J, Shpaner M, et al. The deployment of intersensory selective attention: a high-density electrical mapping study of the effects of theanine. Clin Neuropharmacol. 2007;30(1):25–38.
  22. Park SK, Jung IC, Lee WK, Lee YS, Park HK, Go HJ, et al. A combination of green tea extract and l-theanine improves memory and attention in subjects with mild cognitive impairment: a double-blind placebo-controlled study. J Med Food. 2011 Apr;14(4):334–43.
  23. Baba Y, Inagaki S, Nakagawa S, Kaneko T, Kobayashi M, Takihara T. Effects of l-Theanine on Cognitive Function in Middle-Aged and Older Subjects: A Randomized Placebo-Controlled Study. J Med Food. 2021 Apr;24(4):333–41.
  24. Hidese S, Ogawa S, Ota M, Ishida I, Yasukawa Z, Ozeki M, et al. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients. 2019 Oct;11(10).
  25. Yoto A, Motoki M, Murao S, Yokogoshi H. Effects of L-theanine or caffeine intake on changes in blood pressure under physical and psychological stresses. J Physiol Anthropol. 2012 Oct;31(1):28.
  26. Williams JL, Everett JM, D’Cunha NM, Sergi D, Georgousopoulou EN, Keegan RJ, et al. The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review. Plant Foods Hum Nutr. 2020 Mar;75(1):12–23.
  27. Hammi C, Yeung B. Neuropathy. StatPearls. Treasure Island, FL: StatPearls Publishing.[Google Scholar]; 2021.
  28. Hakim M, Kurniani N, Pinzon RT, Tugasworo D, Basuki M, Haddani H, et al. Management of peripheral neuropathy symptoms with a fixed dose combination of high-dose vitamin B1, B6 and B12: A 12-week prospective non-interventional study in Indonesia. Asian J Med Sci [Internet]. 2018 Jan 1;9(1 SE-Original Articles):32–40. Available from: https://www.nepjol.info/index.php/AJMS/article/view/18510
  29. Hakim M, Kurniani N, Pinzon R, Tugasworo D, M B, H H, et al. A Review on Prevalence and Causes of Peripheral Neuropathy and Treatment of Different Etiologic Subgroups with Neurotropic B Vitamins. J Clin Exp Pharmacol. 2019 Jan 1;9.
  30. D Loew R Wanitschke AS. Studies on Vitamin B12 Status in the Elderly – Prophylactic and Therapeutic Consequences. IJVNR. 1999;69(3):228–33.
  31. Calderón-Ospina CA, Nava-Mesa MO. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther [Internet]. 2020 Jan 1;26(1):5–13. Available from: https://doi.org/10.1111/cns.13207
  32. Huck CJ, Johnston CS, Beezhold BL, Swan PD. Vitamin C status and perception of effort during exercise in obese adults adhering to a calorie-reduced diet. Nutrition. 2013 Jan;29(1):42–5.
  33. Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins. Vitamins E and C, beta-carotene, and other carotenoids. Ann N Y Acad Sci. 1992 Sep;669:7–20.
  34. McCall SJ, Clark AB, Luben RN, Wareham NJ, Khaw KT, Myint PK. Plasma Vitamin C Levels: Risk Factors for Deficiency and Association with Self-Reported Functional Health in the European Prospective Investigation into Cancer-Norfolk. Nutrients. 2019 Jul;11(7).
  35. Gariballa S. Poor vitamin C status is associated with increased depression symptoms following acute illness in older people. Int J Vitam Nutr Res Int  Zeitschrift fur Vitamin- und Ernahrungsforschung J Int Vitaminol Nutr. 2014;84(1–2):12–7.
  36. Pullar JM, Carr AC, Bozonet SM, Vissers MCM. High Vitamin C Status Is Associated with Elevated Mood in Male Tertiary Students. Antioxidants (Basel, Switzerland). 2018 Jul;7(7).
  37. Brouwer-Brolsma EM, de Groot LCPGM. Vitamin D and cognition in older adults: an update of recent findings. Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):11–6.
  38. Annweiler C. Vitamin D in dementia prevention. Ann N Y Acad Sci. 2016 Mar;1367(1):57–63.
  39. Laughlin GA, Kritz-Silverstein D, Bergstrom J, Reas ET, Jassal SK, Barrett-Connor E, et al. Vitamin D Insufficiency and Cognitive Function Trajectories in Older Adults: The Rancho Bernardo Study. J Alzheimers Dis. 2017;58(3):871–83.
  40. Latimer CS, Brewer LD, Searcy JL, Chen KC, Popović J, Kraner SD, et al. Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci U S A. 2014 Oct;111(41):E4359-66.
  41. Anjum I, Jaffery SS, Fayyaz M, Samoo Z, Anjum S. The Role of Vitamin D in Brain Health: A Mini Literature Review. Cureus. 2018 Jul;10(7):e2960.
  42. Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2013;33(3):659–74.
  43. Morais JBS, Severo JS, Santos LR Dos, de Sousa Melo SR, de Oliveira Santos R, de Oliveira ARS, et al. Role of Magnesium in Oxidative Stress in Individuals with Obesity. Biol Trace Elem Res. 2017 Mar;176(1):20–6.
  44. Rock E, Astier C, Lab C, Vignon X, Gueux E, Motta C, et al. Dietary magnesium deficiency in rats enhances free radical production in skeletal muscle. J Nutr. 1995 May;125(5):1205–10.
  45. Derom ML, Sayón-Orea C, Martínez-Ortega JM, Martínez-González MA. Magnesium and depression: a systematic review. Nutr Neurosci. 2013 Sep;16(5):191–206.
  46. Li B, Lv J, Wang W, Zhang D. Dietary magnesium and calcium intake and risk of depression in the general population: A meta-analysis. Aust N Z J Psychiatry. 2017 Mar;51(3):219–29.
  47. Cheungpasitporn W, Thongprayoon C, Qian Q. Dysmagnesemia in Hospitalized Patients: Prevalence and Prognostic Importance. Mayo Clin Proc. 2015 Aug;90(8):1001–10.
  48. Veronese N, Zurlo A, Solmi M, Luchini C, Trevisan C, Bano G, et al. Magnesium Status in Alzheimer’s Disease: A Systematic Review. Am J Alzheimers Dis Other Demen. 2016 May;31(3):208–13.
  49. Zhang Y, Chen C, Lu L, Knutson KL, Carnethon MR, Fly AD, et al. Association of magnesium intake with sleep duration and sleep quality: findings from the CARDIA study. Sleep. 2022 Apr;45(4).
  50. Boyle NB, Lawton C, Dye L. The Effects of Magnesium Supplementation on Subjective Anxiety and Stress-A Systematic Review. Nutrients. 2017 Apr;9(5).
  51. Rajizadeh A, Mozaffari-Khosravi H, Yassini-Ardakani M, Dehghani A. Effect of magnesium supplementation on depression status in depressed patients with magnesium deficiency: A randomized, double-blind, placebo-controlled trial. Nutrition. 2017 Mar;35:56–60.
  52. Hellhammer J, Hero T, Franz N, Contreras C, Schubert M. Omega-3 fatty acids administered in phosphatidylserine improved certain aspects of high chronic stress in men. Nutr Res. 2012 Apr;32(4):241–50.
  53. Jäger R, Purpura M, Geiss KR, Weiß M, Baumeister J, Amatulli F, et al. The effect of phosphatidylserine on golf performance. J Int Soc Sports Nutr. 2007 Dec;4:23.
  54. Schreiber S, Kampf-Sherf O, Gorfine M, Kelly D, Oppenheim Y, Lerer B. An open trial of plant-source derived phosphatydilserine for treatment of age-related cognitive decline. Isr J Psychiatry Relat Sci. 2000;37(4):302–7.
  55. Vakhapova V, Cohen T, Richter Y, Herzog Y, Kam Y, Korczyn AD. Phosphatidylserine containing omega-3 Fatty acids may improve memory abilities in nondemented elderly individuals with memory complaints: results from an open-label extension study. Dement Geriatr Cogn Disord. 2014;38(1–2):39–45.
  56. Parker AG, Gordon J, Thornton A, Byars A, Lubker J, Bartlett M, et al. The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise. J Int Soc Sports Nutr. 2011 Oct;8:16.
  57. Kato-Kataoka A, Sakai M, Ebina R, Nonaka C, Asano T, Miyamori T. Soybean-Derived Phosphatidylserine Improves Memory Function of the Elderly Japanese Subjects with Memory Complaints. J Clin Biochem Nutr. 2010;47(3):246–55.
  58. Hirayama S, Terasawa K, Rabeler R, Hirayama T, Inoue T, Tatsumi Y, et al. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet  Off J Br  Diet Assoc. 2014 Apr;27 Suppl 2:284–91.
  59. Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, et al. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry. 2012 Jul;27(5):335–42.
  60. Engel RR, Satzger W, Günther W, Kathmann N, Bove D, Gerke S, et al. Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. Eur Neuropsychopharmacol  J Eur Coll  Neuropsychopharmacol. 1992 Jun;2(2):149–55.
  61. Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer’s disease. Psychopharmacol Bull. 1992;28(1):61–6.
  62. Argentiero V, Tavolato B. Dopamine (DA) and serotonin metabolic levels in the cerebrospinal fluid (CSF) in Alzheimer’s presenile dementia under basic conditions and after stimulation with cerebral cortex phospholipids (BC-PL). J Neurol. 1980;224(1):53–8.
  63. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998 Aug;3(4):271–80.
  64. Gong P, Liu J, Blue PR, Li S, Zhou X. Serotonin receptor gene (HTR2A) T102C polymorphism modulates individuals’ perspective taking ability and autistic-like traits [Internet]. Vol. 9, Frontiers in Human Neuroscience  . 2015. Available from: https://www.frontiersin.org/articles/10.3389/fnhum.2015.00575
  65. Herman AI, Balogh KN. Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse. Subst Abuse Rehabil. 2012 Jun;3(1):49–57.
  66. Sonkurt MD, Güleç G, Coşan DT, Çalış İU, Mutlu F, Üre İ, et al. Single nucleotide polymorphisms in 5-HT receptors in the etiology of premature ejaculation. Rev Int Andrología [Internet]. 2022;20(4):217–24. Available from: https://www.sciencedirect.com/science/article/pii/S1698031X22000565
  67. Lambe EK, Fillman SG, Webster MJ, Shannon Weickert C. Serotonin Receptor Expression in Human Prefrontal Cortex: Balancing Excitation and Inhibition across Postnatal Development. PLoS One [Internet]. 2011;6(7):1–10. Available from: https://doi.org/10.1371/journal.pone.0022799
  68. Jangid P, Malik P, Singh P, Sharma M, Gulia AKD. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian J Psychiatr. 2013 Feb;6(1):29–34.
  69. Shell W, Bullias D, Charuvastra E, May LA, Silver DS. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep. Am J Ther. 2010;17(2):133–9.
  70. Bruni O, Ferri R, Miano S, Verrillo E. L -5-Hydroxytryptophan treatment of sleep terrors in children. Eur J Pediatr. 2004 Jul;163(7):402–7.
  71. Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S. Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration. Eat Weight Disord. 2012 Mar;17(1):e22-8.
  72. Ceci F, Cangiano C, Cairella M, Cascino A, Del Ben M, Muscaritoli M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm. 1989;76(2):109–17.
  73. Jukić T, Rojc B, Boben-Bardutzky D, Hafner M, Ihan A. The use of a food supplementation with D-phenylalanine, L-glutamine and L-5-hydroxytriptophan in the alleviation of alcohol withdrawal symptoms. Coll Antropol. 2011 Dec;35(4):1225–30.
  74. Schruers K, van Diest R, Nicolson N, Griez E. L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology (Berl). 2002 Jun;161(4):365–9.
  75. Maron E, Tõru I, Vasar V, Shlik J. The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers. J Psychopharmacol. 2004 Jun;18(2):194–9.
  76. Shaw GM, Carmichael SL, Yang W, Selvin S, Schaffer DM. Periconceptional dietary intake of choline and betaine and neural tube defects in offspring. Am J Epidemiol. 2004 Jul;160(2):102–9.
  77. Nurk E, Refsum H, Bjelland I, Drevon CA, Tell GS, Ueland PM, et al. Plasma free choline, betaine and cognitive performance: the Hordaland Health Study. Br J Nutr. 2013 Feb;109(3):511–9.
  78. Poly C, Massaro JM, Seshadri S, Wolf PA, Cho E, Krall E, et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. Am J Clin Nutr. 2011 Dec;94(6):1584–91.
  79. Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol. 2002;213:1–47.
  80. Kiemes A, Davies C, Kempton MJ, Lukow PB, Bennallick C, Stone JM, et al. GABA, Glutamate and Neural Activity: A Systematic Review With Meta-Analysis of Multimodal (1)H-MRS-fMRI Studies. Vol. 12, Frontiers in psychiatry. Switzerland; 2021. p. 644315.
  81. Petroff OAC. GABA and glutamate in the human brain. Neurosci a Rev J bringing Neurobiol Neurol  psychiatry. 2002 Dec;8(6):562–73.
  82. Ngo DH, Vo TS. An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid. Molecules. 2019 Jul;24(15).
  83. Jie F, Yin G, Yang W, Yang M, Gao S, Lv J, et al. Stress in Regulation of GABA Amygdala System and Relevance to Neuropsychiatric Diseases. Front Neurosci. 2018;12:562.
  84. Nemeroff CB. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull. 2003;37(4):133–46.
  85. Gottesmann C. GABA mechanisms and sleep. Neuroscience. 2002;111(2):231–9.
  86. Hepsomali P, Groeger JA, Nishihira J, Scholey A. Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review [Internet]. Vol. 14, Frontiers in Neuroscience  . 2020. Available from: https://www.frontiersin.org/articles/10.3389/fnins.2020.00923
  87. Kulkarni SK, Dhir A. Withania somnifera: an Indian ginseng. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul;32(5):1093–105.
  88. Cheah KL, Norhayati MN, Husniati Yaacob L, Abdul Rahman R. Effect of Ashwagandha (Withania somnifera) extract on sleep: A systematic review and meta-analysis. PLoS One. 2021;16(9):e0257843.
  89. Remenapp A, Coyle K, Orange T, Lynch T, Hooper D, Hooper S, et al. Efficacy of Withania somnifera supplementation on adult’s cognition and mood. J Ayurveda Integr Med. 2022;13(2):100510.
  90. Akhgarjand C, Asoudeh F, Bagheri A, Kalantar Z, Vahabi Z, Shab-Bidar S, et al. Does Ashwagandha supplementation have a beneficial effect on the management of anxiety and stress? A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022 Nov;36(11):4115–24.
  91. Lopresti AL, Smith SJ, Malvi H, Kodgule R. An investigation into the stress-relieving and pharmacological actions of an ashwagandha (Withania somnifera) extract: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019 Sep;98(37):e17186.
  92. Gopukumar K, Thanawala S, Somepalli V, Rao TSS, Thamatam VB, Chauhan S. Efficacy and Safety of Ashwagandha Root Extract on Cognitive Functions in Healthy, Stressed Adults: A Randomized, Double-Blind, Placebo-Controlled Study. Evid Based Complement Alternat Med. 2021;2021:8254344.
  93. Salve J, Pate S, Debnath K, Langade D. Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study. Cureus. 2019 Dec;11(12):e6466.
  94. Fuladi S, Emami SA, Mohammadpour AH, Karimani A, Manteghi AA, Sahebkar A. Assessment of the Efficacy of Withania somnifera Root Extract in Patients with Generalized Anxiety Disorder: A Randomized Double-blind Placebo- Controlled Trial. Curr Rev Clin Exp Pharmacol. 2021;16(2):191–6.
  95. Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012 Jul;34(3):255–62.
  96. Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. 2013 Jul;12(4):312–22.
  97. Panossian A, Hambardzumyan M, Hovhanissyan A, Wikman G. The adaptogens rhodiola and schizandra modify the response to immobilization stress in rabbits by suppressing the increase of phosphorylated stress-activated protein kinase, nitric oxide and cortisol. Drug Target Insights. 2007;2:39–54.
  98. Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, et al. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine. 2015 Mar;22(3):394–9.
  99. Amsterdam JD, Panossian AG. Rhodiola rosea L. as a putative botanical antidepressant. Phytomedicine. 2016 Jun;23(7):770–83.
  100. Edwards D, Heufelder A, Zimmermann A. Therapeutic effects and safety of Rhodiola rosea extract WS® 1375 in subjects with life-stress symptoms–results of an open-label study. Phytother Res. 2012 Aug;26(8):1220–5.
  101. Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. Rhodiola rosea in stress induced fatigue–a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine. 2000 Oct;7(5):365–71.
  102. Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin V V. A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine. 2000 Apr;7(2):85–9.
  103. Shevtsov VA, Zholus BI, Shervarly VI, Vol’skij VB, Korovin YP, Khristich MP, et al. A randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine. 2003 Mar;10(2–3):95–105.
  104. Zhao Q, Tang XC. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol. 2002 Nov;455(2–3):101–7.
  105. Zhang HY. New insights into huperzine A for the treatment of Alzheimer’s disease. Acta Pharmacol Sin. 2012 Sep;33(9):1170–5.
  106. Ved HS, Koenig ML, Dave JR, Doctor BP. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport. 1997 Mar;8(4):963–8.
  107. Ohba T, Nakamura S, Shimazawa M, Hayashi Y, Kono H, Hara H. Protective effects of Huperzia serrata and its components against oxidative damage and cognitive dysfunction. PharmaNutrition [Internet]. 2020;13:100203. Available from: https://www.sciencedirect.com/science/article/pii/S2213434420300281
  108. Inestrosa NC, Alvarez A, Pérez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron. 1996 Apr;16(4):881–91.
  109. Alvarez A, Alarcón R, Opazo C, Campos EO, Muñoz FJ, Calderón FH, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J Neurosci  Off J Soc  Neurosci. 1998 May;18(9):3213–23.
  110. Lei Y, Yang L, Ye CY, Qin MY, Yang HY, Jiang HL, et al. Involvement of intracellular and mitochondrial Aβ in the ameliorative effects of huperzine A against oligomeric Aβ42-induced injury in primary rat neurons. PLoS One. 2015;10(5):e0128366.
  111. Yang L, Ye C yan, Huang X tian, Tang X can, Zhang H yan. Decreased accumulation of subcellular amyloid-β with improved mitochondrial function mediates the neuroprotective effect of huperzine A. J Alzheimer’s Dis. 2012;31(1):131–42.
  112. Wang CY, Zheng W, Wang T, Xie JW, Wang SL, Zhao BL, et al. Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model. Neuropsychopharmacol  Off Publ Am Coll  Neuropsychopharmacol. 2011 Apr;36(5):1073–89.
  113. Xing SH, Zhu CX, Zhang R, An L. Huperzine a in the treatment of Alzheimer’s disease and vascular dementia: a meta-analysis. Evid Based Complement Alternat Med. 2014;2014:363985.
  114. Zheng W, Xiang YQ, Ungvari GS, Chiu FKH, H Ng C, Wang Y, et al. Huperzine A for treatment of cognitive impairment in major depressive disorder: a systematic review of randomized controlled trials. Shanghai Arch psychiatry. 2016 Apr;28(2):64–71.
  115. Kim SR, Hwang SY, Jang YP, Park MJ, Markelonis GJ, Oh TH, et al. Protopine from Corydalis ternata has anticholinesterase and antiamnesic activities. Planta Med. 1999 Apr;65(3):218–21.
  116. Xiao X, Liu J, Hu J, Li T, Zhang Y. Protective effect of protopine on the focal cerebral ischaemic injury in rats. Basic Clin Pharmacol Toxicol. 2007;101(2):85–9.
  117. Kim DK, Lee KT, Baek NI, Kim SH, Park HW, Lim JP, et al. Acetylcholinesterase inhibitors from the aerial parts of Corydalis speciosa. Arch Pharm Res. 2004 Nov;27(11):1127–31.
  118. Sreenivasmurthy SG, Iyaswamy A, Krishnamoorthi S, Senapati S, Malampati S, Zhu Z, et al. Protopine promotes the proteasomal degradation of pathological tau in Alzheimer’s disease models via HDAC6 inhibition. Phytomedicine. 2022 Feb;96:153887.
  119. Eckert A. Mitochondrial effects of Ginkgo biloba extract. Int psychogeriatrics. 2012 Aug;24 Suppl 1:S18-20.
  120. Kehr J, Yoshitake S, Ijiri S, Koch E, Nöldner M, Yoshitake T. Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®. Int psychogeriatrics. 2012 Aug;24 Suppl 1:S25-34.
  121. Mashayekh A, Pham DL, Yousem DM, Dizon M, Barker PB, Lin DDM. Effects of Ginkgo biloba on cerebral blood flow assessed by quantitative MR perfusion imaging: a pilot study. Neuroradiology. 2011 Mar;53(3):185–91.
  122. Gavrilova SI, Preuss UW, Wong JWM, Hoerr R, Kaschel R, Bachinskaya N. Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry. 2014 Oct;29(10):1087–95.
  123. Mix JA, Crews WDJ. An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med. 2000 Jun;6(3):219–29.
  124. Heiss C, Finis D, Kleinbongard P, Hoffmann A, Rassaf T, Kelm M, et al. Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week. J Cardiovasc Pharmacol. 2007 Feb;49(2):74–80.
  125. Vlachopoulos C, Aznaouridis K, Alexopoulos N, Economou E, Andreadou I, Stefanadis C. Effect of dark chocolate on arterial function in healthy individuals. Am J Hypertens. 2005 Jun;18(6):785–91.
  126. Wirtz PH, von Känel R, Meister RE, Arpagaus A, Treichler S, Kuebler U, et al. Dark chocolate intake buffers stress reactivity in humans. Vol. 63, Journal of the American College of Cardiology. United States; 2014. p. 2297–9.
  127. von Känel R, Meister RE, Stutz M, Kummer P, Arpagaus A, Huber S, et al. Effects of dark chocolate consumption on the prothrombotic response to acute psychosocial stress in healthy men. Thromb Haemost. 2014 Dec;112(6):1151–8.
  128. Pase MP, Scholey AB, Pipingas A, Kras M, Nolidin K, Gibbs A, et al. Cocoa polyphenols enhance positive mood states but not cognitive performance: a randomized, placebo-controlled trial. J Psychopharmacol. 2013 May;27(5):451–8.
  129. Macht M, Mueller J. Immediate effects of chocolate on experimentally induced mood states. Appetite. 2007 Nov;49(3):667–74.
  130. Zhu N, Liang X, Zhang M, Yin X, Yang H, Zhi Y, et al. Astaxanthin protects cognitive function of vascular dementia. Behav Brain Funct [Internet]. 2020;16(1):10. Available from: https://doi.org/10.1186/s12993-020-00172-8
  131. Sekikawa T, Kizawa Y, Li Y, Takara T. Cognitive function improvement with astaxanthin and tocotrienol intake: a randomized, double-blind, placebo-controlled study. J Clin Biochem Nutr. 2020 Nov;67(3):307–16.
  132. Zhu S, Liu F, Zhang R, Xiong Z, Zhang Q, Hao L, et al. Neuroprotective Potency of Neolignans in Magnolia officinalis Cortex Against Brain Disorders. Vol. 13, Frontiers in pharmacology. Switzerland; 2022. p. 857449.
  133. Dai X, Xie L, Liu K, Liang Y, Cao Y, Lu J, et al. The Neuropharmacological Effects of Magnolol and Honokiol: A Review of Signal Pathways and Molecular Mechanisms. Curr Mol Pharmacol. 2023;16(2):161–77.
  134. Wang X, Duan X, Yang G, Zhang X, Deng L, Zheng H, et al. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One. 2011 Apr;6(4):e18490.
  135. Rickert U, Cossais F, Heimke M, Arnold P, Preuße-Prange A, Wilms H, et al. Anti-inflammatory properties of Honokiol in activated primary microglia and astrocytes. J Neuroimmunol. 2018 Oct;323:78–86.
  136. Xie Z, Zhao J, Wang H, Jiang Y, Yang Q, Fu Y, et al. Magnolol alleviates Alzheimer’s disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ. Biomed Pharmacother. 2020 Apr;124:109886.
  137. Zhou H, Jiao G, Dong M, Chi H, Wang H, Wu W, et al. Orthosilicic Acid Accelerates Bone Formation in Human Osteoblast-Like Cells Through the PI3K-Akt-mTOR Pathway. Biol Trace Elem Res. 2019 Aug;190(2):327–35.
  138. Chen HH, Chang PC, Wey SP, Chen PM, Chen C, Chan MH. Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARγ regulation. Biomed Pharmacother. 2018 Dec;108:254–62.
  139. Huang SY, Tai SH, Chang CC, Tu YF, Chang CH, Lee EJ. Magnolol protects against ischemic-reperfusion brain damage following oxygen-glucose deprivation and transient focal cerebral ischemia. Int J Mol Med. 2018 Apr;41(4):2252–62.
  140. Kantham S, Chan S, McColl G, Miles JA, Veliyath SK, Deora GS, et al. Effect of the Biphenyl Neolignan Honokiol on Aβ(42)-Induced Toxicity in Caenorhabditis elegans, Aβ(42) Fibrillation, Cholinesterase Activity, DPPH Radicals, and Iron(II) Chelation. ACS Chem Neurosci. 2017 Sep;8(9):1901–12.
  141. Lee YJ, Choi DY, Yun YP, Han SB, Kim HM, Lee K, et al. Ethanol extract of Magnolia officinalis prevents lipopolysaccharide-induced memory deficiency via its antineuroinflammatory and antiamyloidogenic effects. Phytother Res. 2013 Mar;27(3):438–47.
  142. Kubo M. [Search of Neurotrophin-mimic Natural Products for Prevention and Treatment of Neurodegenerative Disease]. Yakugaku Zasshi. 2015;135(10):1147–52.
  143. Qu WM, Yue XF, Sun Y, Fan K, Chen CR, Hou YP, et al. Honokiol promotes non-rapid eye movement sleep via the benzodiazepine site of the GABA(A) receptor in mice. Br J Pharmacol. 2012 Oct;167(3):587–98.
  144. Das S, Pukala TL, Smid SD. Exploring the Structural Diversity in Inhibitors of α-Synuclein Amyloidogenic Folding, Aggregation, and Neurotoxicity. Front Chem. 2018;6:181.
  145. Mucci M, Carraro C, Mancino P, Monti M, Papadia LS, Volpini G, et al. Soy isoflavones, lactobacilli, Magnolia bark extract, vitamin D3 and calcium. Controlled clinical study in menopause. Minerva Ginecol. 2006 Aug;58(4):323–34.
  146. Agosta C, Atlante M, Benvenuti C. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause. Minerva Ginecol. 2011 Feb;63(1):11–7.
  147. Xue L, Zhang J, Shen H, Ai L, Wu R. A randomized controlled pilot study of the effectiveness of magnolia tea on alleviating depression in postnatal women. Food Sci Nutr. 2020 Mar;8(3):1554–61.
  148. Garrison R, Chambliss WG. Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial. Altern Ther Health Med. 2006;12(1):50–4.
  149. Kalman DS, Feldman S, Feldman R, Schwartz HI, Krieger DR, Garrison R. Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J. 2008 Apr;7:11.
  150. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010 Nov;6(6):456–64.
  151. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids. 2009;81(2–3):213–21.
  152. Fiala M, Lau YCC, Aghajani A, Bhargava S, Aminpour E, Kaczor-Urbanowicz KE, et al. Omega-3 Fatty Acids Increase Amyloid-β Immunity, Energy, and Circadian Rhythm for Cognitive Protection of Alzheimer’s Disease Patients Beyond Cholinesterase Inhibitors. J Alzheimers Dis. 2020;75(3):993–1002.
  153. Keppel Hesselink JM, Kopsky DJ. Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res. 2015;8:729–34.
  154. Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacol Res. 2014 Aug;86:32–41.